Glucose-6-phosphate dehydrogenase deficiency

What is Glucose-6-phosphate dehydrogenase deficiency?

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, also known as favism, is an inherited blood disorder that affects red blood cells’ ability to protect themselves from oxidative damage. When people with G6PD deficiency are exposed to certain triggers like specific foods, medications, or infections, their red blood cells can break down rapidly, causing episodes of hemolytic anemia. This X-linked genetic condition affects approximately 400 million people worldwide, making it one of the most common enzyme deficiencies globally. While episodes can be serious, the condition is manageable with proper awareness and avoidance of known triggers.

Key statistics

Symptoms

Primary symptoms: Episodic hemolysis, jaundice, dark urine, fatigue, pale skin, shortness of breath, rapid heart rate, abdominal pain, back pain.

The hallmark of G6PD deficiency is acute hemolytic episodes triggered by oxidative stress. During these episodes, patients develop sudden onset of fatigue and weakness as red blood cells are destroyed faster than they can be replaced. Jaundice becomes apparent as yellowing of the skin and whites of the eyes due to elevated bilirubin from red cell breakdown. Dark-colored urine, often described as cola or tea-colored, results from hemoglobin being filtered through the kidneys.

Many people with G6PD deficiency remain completely asymptomatic between episodes. However, during acute hemolytic crises, patients may experience shortness of breath, rapid heartbeat, and dizziness due to anemia. Some individuals report back or abdominal pain during episodes. In severe cases, patients may develop signs of severe anemia including extreme pallor, confusion, and cardiovascular stress. Newborns with G6PD deficiency may develop prolonged neonatal jaundice requiring phototherapy or exchange transfusion.

Submit Your Paper

Causes and risk factors

G6PD deficiency is caused by mutations in the G6PD gene located on the X chromosome. This gene provides instructions for making the glucose-6-phosphate dehydrogenase enzyme, which plays a crucial role in protecting red blood cells from oxidative damage. More than 400 different variants of the G6PD gene have been identified, with varying degrees of enzyme activity.

The inheritance pattern is X-linked, meaning the gene is located on the X chromosome. Males, having only one X chromosome, are more severely affected when they inherit a defective copy. Females, with two X chromosomes, are typically carriers but may experience mild symptoms due to X-inactivation patterns.

Risk factors for hemolytic episodes include exposure to oxidizing agents such as certain medications (antimalarials like primaquine, sulfonamides, aspirin in high doses), foods (fava beans, which give the condition its alternate name “favism”), infections, diabetic ketoacidosis, and severe physical stress. The severity and triggers vary significantly depending on the specific genetic variant involved.

Prevention

There is no way to prevent G6PD deficiency itself as it is an inherited genetic condition. However, hemolytic episodes are entirely preventable through trigger avoidance and proper medical management.

Genetic counseling and carrier testing are essential for families with a history of G6PD deficiency. Prenatal testing is available for at-risk pregnancies. Newborn screening programs in many countries help identify affected infants early, preventing severe neonatal complications.

Primary prevention focuses on education about trigger avoidance, including maintaining an updated list of medications to avoid and ensuring all healthcare providers are aware of the diagnosis. Patients should be counseled about dietary restrictions, particularly avoiding fava beans and other foods high in oxidants. Prompt treatment of infections and maintaining good general health help reduce the risk of oxidative stress that can trigger episodes.

Complications

Without proper management, G6PD deficiency can lead to severe and potentially life-threatening complications. Acute severe hemolysis can result in profound anemia requiring emergency blood transfusion. In extreme cases, massive hemolysis can lead to kidney failure due to hemoglobin blocking kidney tubules.

Chronic complications are rare but may include gallstones due to increased bilirubin production from ongoing low-level hemolysis. Prolonged or repeated episodes of severe anemia can affect growth and development in children. Neonatal complications include severe jaundice that may cause kernicterus (brain damage) if untreated.

Psychological impacts include anxiety about trigger exposure and lifestyle limitations. Some patients develop medical alert awareness fatigue, leading to decreased vigilance about trigger avoidance over time. Social complications may arise from dietary restrictions and the need for medical alert identification.

Diagnosis

Diagnosis of G6PD deficiency involves specific laboratory testing to measure enzyme activity. The quantitative G6PD enzyme assay is the gold standard, measuring actual enzyme activity levels in red blood cells. However, this test can be falsely normal during or immediately after hemolytic episodes when older, more enzyme-deficient cells have been destroyed.

The fluorescent spot test provides rapid screening but may miss milder variants. Molecular genetic testing can identify specific mutations and provide definitive diagnosis regardless of when the test is performed. Complete blood count during episodes shows anemia, elevated reticulocyte count, and sometimes fragmented red blood cells.

Laboratory findings during hemolytic episodes include elevated indirect bilirubin, decreased haptoglobin, elevated lactate dehydrogenase, and hemoglobinuria. Peripheral blood smear may show bite cells, blister cells, and increased reticulocytes. Family history and ethnic background provide important diagnostic clues, as certain variants are more common in specific populations.

Treatment

Treatment of G6PD deficiency focuses primarily on trigger avoidance and supportive care during hemolytic episodes. There is no specific cure for the enzyme deficiency itself.

During acute hemolytic episodes, treatment includes discontinuation of any triggering agents, supportive care with hydration, and monitoring for complications. Severe anemia may require blood transfusion. Folic acid supplementation supports increased red blood cell production during recovery.

Pain management may be necessary during episodes, typically with acetaminophen (avoiding aspirin). Treatment of underlying infections that trigger episodes often includes antibiotics, carefully selected to avoid those known to cause hemolysis in G6PD deficiency.

Preventive measures include patient education about trigger avoidance, medical alert identification, and regular follow-up with healthcare providers familiar with the condition. Some patients benefit from carrying emergency information cards listing safe and unsafe medications.

Prognosis

The prognosis for G6PD deficiency is generally excellent with proper management and trigger avoidance. Most individuals live completely normal lives between episodes, with normal life expectancy and quality of life. The key to good outcomes is education about trigger avoidance and prompt recognition of hemolytic episodes.

Without proper awareness and management, severe episodes can be life-threatening, particularly in children or individuals with other health conditions. However, with appropriate medical care and lifestyle modifications, serious complications are rare. Many people with milder variants may go years or even decades without experiencing hemolytic episodes.

The prognosis varies significantly depending on the specific G6PD variant, with some causing more severe enzyme deficiency than others. Access to healthcare and medication safety awareness also significantly impact outcomes. Early diagnosis through newborn screening programs dramatically improves prognosis by enabling early education and prevention strategies.

Quality of life

Most people with G6PD deficiency maintain excellent quality of life through proper management strategies. Daily life requires some awareness and precautions, but these typically become routine with time and education.

Dietary modifications primarily involve avoiding fava beans and being cautious with other potentially oxidizing foods during illness. Regular exercise and physical activity are generally safe and encouraged, though patients should be aware that severe physical stress can occasionally trigger mild hemolysis.

Mental health support may be beneficial for some individuals who experience anxiety about potential triggers or feel restricted by necessary precautions. Building confidence through education about the condition helps many patients feel more in control of their health.

Work and school activities are typically unaffected, though patients should ensure that occupational health services are aware of medication restrictions. Travel requires planning to ensure access to safe medications and medical care if needed. Many patients find that wearing medical alert jewelry provides peace of mind and ensures appropriate medical care in emergency situations.

Pregnancy and fertility

G6PD deficiency does not typically affect fertility in either men or women. However, pregnancy requires special consideration for both medication safety and genetic counseling.

Pregnant women with G6PD deficiency need careful medication selection, as some antibiotics and other drugs commonly used during pregnancy can trigger hemolysis. Close collaboration between obstetricians and hematologists helps ensure safe medication choices throughout pregnancy and delivery.

Genetic counseling is essential for couples where one or both partners have G6PD deficiency or are carriers. Since the condition is X-linked, affected fathers will pass the gene to all daughters (who become carriers) but no sons. Carrier mothers have a 50% chance of passing the gene to each child. Prenatal testing is available for at-risk pregnancies.

Breastfeeding is generally safe, though mothers should continue avoiding trigger medications as some drugs can be transmitted through breast milk and potentially affect nursing infants with G6PD deficiency.

Children

G6PD deficiency in children requires special attention to prevent severe complications. Newborn screening identifies many affected infants early, allowing for prompt education and prevention strategies.

Neonatal jaundice is more common and may be more severe in babies with G6PD deficiency, sometimes requiring phototherapy or exchange transfusion. Parents must be educated about trigger avoidance, including being cautious with over-the-counter medications and herbal remedies.

School health personnel should be informed about the child’s condition and medication restrictions. Teachers and caregivers need to understand the importance of avoiding certain medications and recognizing signs of hemolytic episodes. Emergency action plans help ensure appropriate care if symptoms develop at school.

Growth and development are typically normal with proper management. Children should be encouraged to participate in age-appropriate activities while learning about their condition in developmentally appropriate ways. Adolescents need comprehensive education about trigger avoidance as they gain independence and may encounter new situations involving medications or substances.

When to see a doctor

Immediate medical attention is required for symptoms of acute hemolysis including sudden fatigue, jaundice, dark urine, shortness of breath, rapid heartbeat, or severe weakness. These symptoms, especially when occurring after exposure to known triggers, constitute medical emergencies requiring prompt evaluation and treatment.

Routine medical care should include regular check-ups with healthcare providers familiar with G6PD deficiency. Patients should consult their doctor before taking any new medications, including over-the-counter drugs and supplements. Any planned medical procedures or surgeries require advance discussion about safe medication options.

Parents should seek immediate care if children with G6PD deficiency develop signs of illness, as infections can trigger hemolytic episodes. Prolonged or severe jaundice in newborns requires urgent medical evaluation. Any concerning symptoms or questions about trigger avoidance warrant consultation with healthcare providers.

Regional context

G6PD deficiency shows significant geographic variation in prevalence and variant types. In the Caucasus region and Eastern Mediterranean, certain variants may be more common, though specific prevalence data for Georgia, Armenia, and Azerbaijan requires further research documentation.

Mediterranean variants, including G6PD Mediterranean, are historically associated with severe enzyme deficiency and significant trigger sensitivity. Healthcare systems in these regions benefit from awareness of local variant patterns and trigger sensitivities.

We invite contributions from medical professionals in the Caucasus region to help Global Medical Journal provide more specific information about local prevalence, common variants, and healthcare resources for G6PD deficiency in Georgia, Armenia, and Azerbaijan.

Research and clinical trials

Current research focuses on gene therapy approaches, enzyme replacement strategies, and development of safer alternatives to triggering medications. Several studies investigate the relationship between G6PD deficiency and protection against malaria, exploring potential therapeutic applications.

Pharmaceutical research aims to develop antimalarial drugs that are safe for people with G6PD deficiency, addressing a major global health challenge. Studies of antioxidant supplementation show promise for reducing episode frequency in some patients.

Patients interested in clinical trials can search ClinicalTrials.gov for current studies. Research registries help connect patients with ongoing studies and contribute to advancement of treatment options. Participation in research studies helps improve understanding and treatment of G6PD deficiency for future patients.

Frequently asked questions

Can people with G6PD deficiency take any painkillers safely?

Yes, acetaminophen is generally safe for people with G6PD deficiency. However, aspirin and some other pain medications should be avoided. Always consult your doctor before taking any new medications.

Is G6PD deficiency the same as sickle cell disease?

No, these are different conditions. Both affect red blood cells and can cause anemia, but they have different causes, inheritance patterns, and treatments. G6PD deficiency is an enzyme deficiency, while sickle cell disease affects hemoglobin structure.

Can women be affected by G6PD deficiency?

Yes, though less commonly than men. Women can be carriers and may experience mild symptoms, or rarely can be fully affected if they inherit defective genes from both parents or have certain chromosomal patterns.

Do I need to avoid all beans if I have G6PD deficiency?

Not necessarily. Fava beans (broad beans) are the primary concern and should be strictly avoided. Other beans are generally safe, but individual sensitivity can vary. Discuss dietary restrictions with your healthcare provider.

Can G6PD deficiency be cured?

Currently, there is no cure for G6PD deficiency. However, the condition is highly manageable through trigger avoidance and appropriate medical care. Research into gene therapy and other treatments continues.

Support and resources

International Organizations:
– World Health Organization (WHO): www.who.int
– National Organization for Rare Disorders (NORD): rarediseases.org
– Orphanet: www.orpha.net
– EURORDIS: www.eurordis.org

Patient Organizations:
– G6PD Deficiency Foundation: www.g6pd.org
– Global Genes: globalgenes.org
– Genetic Alliance: www.geneticalliance.org

Related conditions

– Hereditary spherocytosis
– Pyruvate kinase deficiency
– Sickle cell disease
– Thalassemia
– Autoimmune hemolytic anemia

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.